Sino Biopharm Completes Phase I Study of Hepatitis B Drug
Sino Biopharmaceutical (HKG:1177) said it recently successfully completed the phase I clinical study of its self-developed drug TQA3038 (siRNA), according to a Thursday filing with the Hong Kong Excha
Express News | China Biopharmaceutical: Class 1 innovative drug TQA3038 (siRNA has completed phase I clinical research
China Biopharmaceuticals (01177.HK) received 2 million additional shares from Chairman Xie Qirun
Gelonghui, April 24 | According to the latest equity disclosure data of the Stock Exchange, on April 23, 2024, China Biopharmaceutical (01177.HK) was granted an increase of 2 million shares at an average price of HK$2.5891 per share on the market, involving approximately HK$5.1782 million. After the increase in holdings, Xie Qirun's latest shareholding was 6 million shares, and the shareholding ratio increased from 0.02% to 0.03%.
The majority shareholders of Chinese biopharmaceuticals continued to increase their holdings, and the fund focused on increasing their holdings in the first quarter
China Biopharmaceutical (01177.HK) obtained Xie Qirun to increase its common shares by 2 million shares, worth approximately HK$5.178,200
On April 23, it was reported that according to the documents disclosed by the Hong Kong Stock Exchange on April 23, Xie Qirun increased its common share holdings of $China Biopharmaceutical (01177.HK) by $2 million at an average price of HK$2.5891 per share on April 23, worth about HK$5.178,200. After the increase in holdings, Xie Qirun's latest shareholding was 6 million shares, and the good position ratio increased from 0.02% to 0.03%. Photo Source: Stock Exchange Equity Disclosure What is equity disclosure? As required by the Hong Kong Stock Exchange, major shareholders (individuals and companies holding 5% or more of the shares) are required to disclose their share interests in listed companies. Listed public
China Biopharmaceuticals (01177.HK) gains 5 million shares by Executive Director Xie Chengrun
Gelonghui, April 23 | According to the latest equity disclosure data of the Stock Exchange, on April 19, 2024, China Biopharmaceutical (01177.HK) was granted an increase of 5 million shares by Executive Director Xie Chengrun on the market at an average price of HK$239 per share, involving approximately HK$116.19,500. After the increase in holdings, Tse Chengyun's latest shareholding was 4,055,000,000 shares, and the shareholding ratio increased from 21.54% to 21.57%.
China Biopharmaceuticals (01177.HK) received 5 million additional shares of common shares by Xie Chengrun, worth approximately HK$11.619,500
On April 22, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on April 22, Xie Chengyun increased his share share holdings of China Biopharmaceuticals (01177.HK) by $5 million at an average price of HK$2.3239 per share on April 19, worth about HK$11.619,500. After the increase in holdings, the latest number of shares held by Xie Chengyun was 4,055 billion shares, and the good position ratio increased from 21.54% to 21.57%. Photo Source: Stock Exchange Equity Disclosure What is equity disclosure? As required by the Hong Kong Stock Exchange, major shareholders (individuals and companies holding 5% or more of the shares) are required to disclose their shares in listed companies
China Biopharmaceuticals rose more than 8%, Meituan and Tencent Holdings rose more than 5%; Ideal Auto fell more than 8%, and Xiaopeng Auto fell nearly 2%.
China Biopharmaceuticals rose more than 8%, Meituan and Tencent Holdings rose more than 5%; Ideal Auto fell more than 8%, and Xiaopeng Auto fell nearly 2%.
Repurchase Collection on April 19 | HSBC Holdings, Hang Seng Bank, etc. bought back one after another, of which HSBC Holdings spent HK$229 million
According to HKEx's April 22 disclosure documents, $HSBC Holdings (00005.HK) $ and $Hang Seng Bank (00011.HK) $ repurchased shares. ① $HSBC Holdings (00005.HK) $ repurchased 3.673,200 common shares on April 18, involving an amount of HK$229 million. The repurchase price per share ranged from HK$62.75 to HK$61.8. ② $Hang Seng Bank (00011.HK) $ repurchased 600,000 common shares on April 19, involving an amount of HK$57,285,300. The repurchase price per share ranged from HK$96.35 to HK$93
Changes in Hong Kong stocks | Zhongsheng Pharmaceuticals (01177) is now up more than 5%, key registration studies on the innovative drug lovaxitinib tablets have reached the main end
Zhongsheng Pharmaceutical (01177) is now up more than 5%. As of press release, it has risen 4.7% to HK$2.45, with a turnover of HK$27.146,500.
China Biopharmaceuticals (01177.HK) received 2.5 million shares from Chairman Xie Qirun
Gelonghui, April 22丨According to the latest equity disclosure data of the Stock Exchange, on April 19, 2024, China Biopharmaceutical (01177.HK) was granted an increase of 2.5 million shares at an average price of HK$2.3223 per share on the market, involving approximately HK$5.8058 million. After the increase in holdings, Xie Qirun's latest shareholding was 4 million shares, and the shareholding ratio increased from 0.01% to 0.02%.
Hong Kong bullish stocks this week | 80% increase in the month! TCL Electronics surged more than 16% this week; CRRC surged nearly 11% the day after
Benefiting from the acceleration of nuclear power approval, CGN's stock price has been rising for five consecutive days; coal supply and demand continued to be tight, and Mongolian coking coal increased by more than 11% during the week.
China Biopharmaceutical (01177.HK) obtained Xie Qirun to increase its common shares by 2.5 million shares, worth approximately HK$5.8057 million
On April 19, it was reported that according to documents disclosed by the Hong Kong Stock Exchange on April 19, Xie Qirun increased its common stock holdings of $2.5 million in China Biopharmaceuticals (01177.HK) at an average price of HK$2.3223 per share on April 19, worth about HK$5.8057 million. After the increase in holdings, Xie Qirun's latest shareholding was 4 million shares, and the good position ratio increased from 0.01% to 0.02%. Photo Source: Stock Exchange Equity Disclosure What is equity disclosure? As required by the Hong Kong Stock Exchange, major shareholders (individuals and companies holding 5% or more of the shares) are required to disclose their share interests in listed companies. Listed public
Sino Biopharmaceutical Reaches Primary Endpoint for Clinical Research of Myelofibrosis Drug
Sino Biopharmaceutical's (HKG:1177) key clinical research for the registration of Rovadicitinib has met its primary endpoint, a Thursday filing on the Hong Kong bourse stated. The pharmaceutical compa
Selected announcements | JD: The first quarter buyback cost 1.2 billion US dollars; Yankuang Energy's commercial coal sales increased by more than 10% in the first quarter
Ideal Auto: The family's five-seater luxury SUV Ideal L6 was officially released; Yankuang Energy: Commercial coal sales in the first quarter were 35.62 million tons, an increase of 11.59% over the previous year.
China Biopharmaceutical (01177.HK): Key registration study on Class 1 innovative rovaxitinib tablets ROVADICITINIB (TQ05105) obtained positive results
Gelonghui, April 18 | China Biopharmaceutical (01177.HK) announced that the key registered clinical study of the Class 1 innovative drug Rovadicitinib (TQ05105), a class 1 innovative drug independently developed by the Group for the treatment of medium- and high-risk myelofibrosis (MF), has reached the main end. The Group has communicated with the Drug Evaluation Center (CDE) of the China National Drug Administration on the marketing application for TQ05105 tablets and obtained the CDE's approval to submit the marketing application for this product. The Group will submit a listing application for TQ05105 in the near future. TQ05105 is a group
Sino Biopharm EBT Buys Back HK$12 Million Worth of Shares
Sino Biopharmaceutical's (HKG:1177) employee benefit trust (EBT) has purchased 5 million of the firm's shares from the secondary market at about HK$2.459 apiece, according to a Wednesday filing with t
China Biopharmaceutical (01177.HK): Trustee buys 5 million shares under restricted share award scheme
Gelonghui, April 17, 丨 China Biopharmaceutical (01177.HK) issued an announcement. On April 17, 2024, the trustee purchased an additional 5 million shares from the market and held them in trust on behalf of the selected participants in accordance with the terms and conditions of the program rules.
Repurchase Collection on April 16 | HSBC Holdings, Changshi Group, etc. bought back one after another, of which HSBC Holdings spent HK$206 million
According to documents disclosed by the Hong Kong Stock Exchange on April 17, $HSBC Holdings (00005.HK) $, $Changshi Group (01113.HK) $, etc. repurchased shares. ① $HSBC Holdings (00005.HK) $ repurchased 3.2412 million common shares on April 15, involving an amount of HK$206 million. The repurchase price per share ranged from HK$63.85 to HK$63.1. ② $Changshi Group (01113.HK) $ repurchased 2,434,500 common shares on April 16, involving an amount of HK$76.3271 million, with a repurchase price of HK$31.4 per share
China Biopharmaceutical (01177) spent HK$12.7 million to buy back 5 million shares on April 16
China Biopharmaceutical (01177) announced that on April 16, 2024, the company spent HK$12.7 million...
No Data